Clinical effect of S-1 monotherapy on advanced non-small-cell lung cancer with acquired drug resistance of gefitinib
Huijuan Wang(Beijing Chao-Yang Hospital, Capital Medical University), Guanbin Qi(Zhengzhou University), Peng Li(Jiangsu Academy of Agricultural Sciences), Xiangtao Yan(Zhengzhou University), Hui Zhu(Sun Yat-sen University), Qiming Wang(Hunan Cancer Hospital), Guowei Zhang(Central Hospital of Wuhan)
Cited by 0
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury
|Journal of Neuroinflammation|2013|387
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
MEK inhibitors for the treatment of non-small cell lung cancer
|Journal of Hematology & Oncology|2021|300